Ascentage Pharma Group International (AAPG) shareholders
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AAPG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 13,841 | 0.00% | $243.05K | −2,215 | 0.00% |
| Morgan Stanley | 919 | 0.00% | $16.14K | +421 | 0.00% |
| Wells Fargo & Company/Mn | 200 | 0.00% | $3.51K | New | 0.00% |
| EverSource Wealth Advisors, LLC | 24 | 0.00% | $421 | – | 0.00% |
| UBS Group AG | 15 | 0.00% | $263 | −109 | 0.00% |
| Royal Bank of Canada | 6 | 0.00% | $0 | – | 0.00% |
| BlackRock, Inc. | 6 | 0.00% | $105 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $18 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 0.0% | 3 / 1 | 2 / 2 | 0M | 0M |
| Q1 2026 | 7 | 0M | 0.0% | 0 / 2 | 3 / 5 | 0M | 0M |
| Q4 2025 | 12 | 0M | 0.0% | 2 / 3 | 5 / 3 | 0M | 0M |
| Q3 2025 | 14 | 0M | 0.0% | 6 / 3 | 4 / 4 | 0M | 0M |
| Q2 2025 | 12 | 0M | 0.0% | 9 / 1 | 2 / 3 | 0M | 0M |
| Q1 2025 | 6 | 0M | 0.1% | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
3 funds held AAPG in Q4 2025, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AAPG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 361 | 0.00% | $7.26K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dajun Yang | Chairman and CEO, Director | 37,742,091 | 10.11% | May 22, 2026 |
| Faical Miyara | Chief Business Officer | – | – | Jun 29, 2026 |
| Yifan Zhai | Chief Medical Officer | 37,742,091 | 10.11% | May 22, 2026 |
| Veet Misra | Chief Financial Officer | – | – | Apr 21, 2026 |
| Jin Cao | Chief Accounting Officer | 5,400 | 0.00% | Apr 20, 2026 |
| Thomas J. Knapp | SVP/General Counsel | 362,444 | 0.10% | Mar 23, 2026 |
| Shaomeng Wang | Director | 10,053,943 | 2.69% | Mar 23, 2026 |
| Ren Wei | Director | 8,964 | 0.00% | Mar 23, 2026 |
| Marc E. Lippman | Director | 21,174 | 0.01% | Mar 23, 2026 |
| David Sidransky | Director | 10,641 | 0.00% | Mar 23, 2026 |
| Marina Bozilenko | Director | – | – | Mar 23, 2026 |
| Debra Yu | Director | – | – | Mar 23, 2026 |
| Simon Dazhong Lu | Director | 41,457 | 0.01% | Mar 23, 2026 |
| Changqing Ye | Director | 8,964 | 0.00% | Mar 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yifan Zhai Chief Medical Officer | May 21, 2026 | Option exercise | +92,746 | – | – | 405,280 |
| Yifan Zhai Chief Medical Officer | May 21, 2026 | Option exercise | +95,575 | – | – | 1,193,569 |
| Dajun Yang Chairman and CEO, Director | May 21, 2026 | Option exercise | +95,575 | – | – | 1,193,569 |
| Dajun Yang Chairman and CEO, Director | May 21, 2026 | Option exercise | +92,746 | – | – | 405,280 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ascentage Pharma Group International's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,800 shares on Sep 9, 2026 over the last 90 days.
See a number that looks wrong?